Cargando…
New therapeutic target for pediatric anaplastic ependymoma control: study of anti-tumor activity by a Kunitz-type molecule, Amblyomin-X
EPNs comprise a heterogeneous group of neuroepithelial tumors, accounting for about 10% of all intracranial tumors in children and up to 30% of brain tumors in those younger than 3 years. Actually, the pattern therapy for low-grade EPNs includes complete surgical resection followed by radiation ther...
Autores principales: | Pavon, Lorena Favaro, Capper, David, Sibov, Tatiana Tais, de Toledo, Silvia Regina Caminada, Thomale, Ulrich-W., de Souza, Jean Gabriel, Cabral, Francisco Romero, Berra, Carolina Maria, Silva da Costa, Marcos Devanir, Mendonça Niçacio, Jardel, Dastoli, Patrícia Alessandra, de Oliveira, Daniela Mara, Malheiros, Suzana M. F., da Cruz, Edgar Ferreira, Malheiros, Jackeline Moraes, de Oliveira, Sérgio Mascarenhas, Silva, Nasjla Saba, Petrilli, Antonio Sérgio, Cappellano, Andrea Maria, Brunialti, Milena Colò, Salomão, Reinaldo, de Paiva Neto, Manoel A., Chudzinski-Tavassi, Ana Marisa, Cavalheiro, Sérgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620274/ https://www.ncbi.nlm.nih.gov/pubmed/31292491 http://dx.doi.org/10.1038/s41598-019-45799-4 |
Ejemplares similares
-
Amblyomin-X, a recombinant Kunitz-type inhibitor, regulates cell adhesion and migration of human tumor cells
por: Schmidt, Mariana Costa Braga, et al.
Publicado: (2018) -
Preclinical evaluation of Amblyomin-X, a Kunitz-type protease inhibitor with antitumor activity
por: Maria, Durvanei A., et al.
Publicado: (2018) -
Dynein Function and Protein Clearance Changes in Tumor Cells Induced by a Kunitz-Type Molecule, Amblyomin-X
por: Pacheco, Mario T. F., et al.
Publicado: (2014) -
Establishment of primary cell culture and an intracranial xenograft model of pediatric ependymoma: a prospect for therapy development and understanding of tumor biology
por: Pavon, Lorena Favaro, et al.
Publicado: (2018) -
LGG-43. Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas
por: Dassi, Natália, et al.
Publicado: (2022)